June 25, 2026
Partnership connects China's rapidly expanding CGT innovation ecosystem with European clinical development standards and digital trial infrastructure
Beijing, China & Berlin, Germany – CSGCT（Chinese Society of Gene and Cell Therapy）and Clincase, a Germany-based provider of eClinical software solutions, today announced the signing of a Memorandum of Strategic Cooperation to support the global advancement of cell and gene therapy (CGT) development across China, Europe, and the Asia-Pacific region.
The partnership combines CSGCT's extensive network of leading Chinese CGT investigators, hospitals, research institutions, and industry stakeholders with Clincase's expertise in clinical trial technology, regulatory-compliant data management, and international clinical development. Together, the organizations aim to facilitate cross-border collaboration and accelerate the translation of innovative CGT programs into clinical practice.
China has emerged as one of the world's most dynamic environments for cell and gene therapy innovation, driven by a growing ecosystem of investigator-initiated trials (IITs), world-class clinical institutions, and increasing investment in advanced therapies. Through this partnership, CSGCT and Clincase will work to create new pathways for international biotechnology companies, investors, and research organizations seeking to engage with China's CGT ecosystem.
As part of the collaboration, Clincase will serve as a Global Strategic Cooperation Partner of CSGCT and will participate in the 2026 CSGCT Annual Meeting, to be held on September 19–20, 2026, in Beijing. The conference is expected to bring together thousands of researchers, clinicians, investors, regulators, and industry leaders from around the world to discuss the future of cell and gene therapy.
"China's cell and gene therapy ecosystem is evolving at remarkable speed and is becoming increasingly important to global innovation," said Wu Xuetao, Deputy Secretary General of CSGCT. "Through our collaboration with Clincase, we aim to strengthen international cooperation and help innovative therapies move more efficiently from research to clinical application."
Judy Lux, Co-Founder and COO of Clincase GmbH, commented: "The future of advanced therapies will be built through global collaboration. By combining CSGCT's deep connections within China's CGT ecosystem with Clincase's expertise in clinical technology and international regulatory environments, we hope to create practical pathways that help innovators navigate cross-border clinical development and bring new therapies to patients faster."
The agreement takes effect immediately and will remain in force through June 2027, with the option for renewal upon mutual agreement.
The Chinese Society of Gene & Cell Therapy (CSGCT) is a leading non-profit organization connecting scientists, clinicians, regulators, industry leaders, and investors to advance cell and gene therapy (CGT) innovation globally. By bridging research and real-world application, CSGCT accelerates breakthrough therapies and improves patient outcomes.
The 2026 CSGCT Annual Meeting, the most influential CGT event in the Asia-Pacific region, will be held on September 19–20, 2026 in Beijing. The meeting covers cutting-edge CGT research, technology breakthroughs, policy updates, and international business development — offering a premier platform for market access insights and partnership opportunities, positioning itself as the "Eastern Engine" of the global CGT industry.
Founded in Berlin in 2004, Clincase GmbH provides a comprehensive eClinical Solutions Suite supporting global clinical research.
The company combines European regulatory rigor with Asian operational agility, enabling sponsors, biotechnology companies, and research organizations to conduct efficient, compliant, and data-driven clinical trials worldwide. Through its unique German-Singapore heritage, Clincase serves as a bridge between European and Asian clinical research ecosystems.
From planning to go-live, we design systems that fit your workflow.
-min.webp&w=1200&q=75)
Clincase EDC Implementation: Supporting Real-World Study Workflows
Clincase’s hybrid methodology brings structure and flexibility to every EDC implementation. In this article, our Implementation Manager, Caroline Chong, and her team walk through how that approach takes shape in real-world studies — from understanding complex protocols to delivering tailored system configurations.
How Clincase’s Hybrid Methodology Keeps EDC Implementation Agile, Focused, and On Track
Every successful clinical trial starts with a team that knows how to turn complex protocols into working systems. At Clincase, we use a hybrid project management methodology that blends structure and flexibility to guide EDC implementation from planning through go-live. In this article, developed with our Implementation Manager, Caroline Chong, we explain how her team supports sponsors and CROs by delivering setups that align with operational workflows and meet regulatory requirements.
Why Choosing the Right EDC System Is Critical for Clinical Trial Success
Clinical trials are growing more complex — not just scientifically, but operationally. As protocols evolve and timelines tighten, mid-sized CROs must deliver faster, more tailored trials with leaner teams. Choosing the right EDC system is critical to keeping pace and staying competitive.